HUE057083T2 - C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére - Google Patents

C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére

Info

Publication number
HUE057083T2
HUE057083T2 HUE16852866A HUE16852866A HUE057083T2 HU E057083 T2 HUE057083 T2 HU E057083T2 HU E16852866 A HUE16852866 A HU E16852866A HU E16852866 A HUE16852866 A HU E16852866A HU E057083 T2 HUE057083 T2 HU E057083T2
Authority
HU
Hungary
Prior art keywords
natriuretic peptide
type natriuretic
peptide variants
treat osteoarthritis
osteoarthritis
Prior art date
Application number
HUE16852866A
Other languages
English (en)
Inventor
Charles O'neill
Todd Oppeneer
Jason Pinkstaff
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of HUE057083T2 publication Critical patent/HUE057083T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE16852866A 2015-12-08 2016-12-08 C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére HUE057083T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08

Publications (1)

Publication Number Publication Date
HUE057083T2 true HUE057083T2 (hu) 2022-04-28

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16852866A HUE057083T2 (hu) 2015-12-08 2016-12-08 C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére

Country Status (17)

Country Link
US (2) US11202819B2 (hu)
EP (2) EP3386531B1 (hu)
JP (1) JP7104625B2 (hu)
KR (1) KR20180088459A (hu)
CN (1) CN108697766A (hu)
AU (2) AU2016365751B2 (hu)
CA (1) CA3007315A1 (hu)
DK (1) DK3386531T3 (hu)
ES (1) ES2901769T3 (hu)
HR (1) HRP20211908T1 (hu)
HU (1) HUE057083T2 (hu)
IL (1) IL259690B2 (hu)
MX (1) MX2018006986A (hu)
PL (1) PL3386531T3 (hu)
PT (1) PT3386531T (hu)
RU (2) RU2759679C2 (hu)
WO (1) WO2017100400A2 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
AU2017205694B2 (en) 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
KR20180100624A (ko) 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with reduced side effects
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CA3007982C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
BR112019005351A2 (pt) 2016-09-29 2019-06-11 Ascendis Pharma Growth Disorders As terapia combinada com agonistas de cnp de liberação controlada
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
CN117281783A (zh) * 2019-02-11 2023-12-26 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
WO2022240936A1 (en) * 2021-05-11 2022-11-17 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
TW202334188A (zh) * 2021-12-07 2023-09-01 美商拜奧馬林製藥公司 Ｃｎｐ療法
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US7642243B2 (en) * 2004-03-31 2010-01-05 Kazuwa Nakao Method of treating arthritis and promoting growth of articular chondrocytes
JP4972403B2 (ja) * 2004-03-31 2012-07-11 一和 中尾 身長増加用組成物
CA2705603A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
PL2432489T3 (pl) * 2009-05-20 2017-05-31 Biomarin Pharmaceutical Inc. Warianty peptydu natriuretycznego typu C
US9266939B2 (en) * 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof

Also Published As

Publication number Publication date
AU2016365751B2 (en) 2023-12-21
ES2901769T3 (es) 2022-03-23
US20190247467A1 (en) 2019-08-15
RU2018124600A (ru) 2020-01-13
IL259690A (en) 2018-07-31
AU2024201852A1 (en) 2024-04-11
JP2019505486A (ja) 2019-02-28
DK3386531T3 (da) 2022-01-03
KR20180088459A (ko) 2018-08-03
RU2021132347A (ru) 2022-03-24
EP3386531A2 (en) 2018-10-17
HRP20211908T1 (hr) 2022-03-04
MX2018006986A (es) 2018-09-05
AU2016365751A1 (en) 2018-06-21
US11202819B2 (en) 2021-12-21
EP3386531B1 (en) 2021-10-13
EP4019038A3 (en) 2022-09-28
PT3386531T (pt) 2021-12-29
CA3007315A1 (en) 2017-06-15
PL3386531T3 (pl) 2022-02-28
IL259690B2 (en) 2023-02-01
EP4019038A2 (en) 2022-06-29
US20220160836A1 (en) 2022-05-26
CN108697766A (zh) 2018-10-23
RU2018124600A3 (hu) 2020-01-13
JP7104625B2 (ja) 2022-07-21
WO2017100400A3 (en) 2017-10-26
WO2017100400A2 (en) 2017-06-15
IL259690B (en) 2022-10-01
RU2759679C2 (ru) 2021-11-16

Similar Documents

Publication Publication Date Title
IL259690B (en) Use of c-type natriuretic peptide variants for the treatment of osteoarthritis
IL278488B (en) Use of C-type natriuretic peptide variants. For the treatment of skeletal dysplasia
IL259110A (en) Treatment of osteoarthritis (osteoarthritis)
IL286888A (en) Use of pyridofidine to treat depression and anxiety
IL283258A (en) A preparation for the treatment of hypothyroidism
HK1252816A1 (zh) Tlr8激活劑治療癌症的應用
ZA201705490B (en) Purification of highly saline feeds
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
HK1231380A1 (zh) 嚴重高甘油三酯血症的治療
HK1259032A1 (zh) 曲恩汀將銅遞送到缺血組織的用途
PL3191170T3 (pl) Plaster zdolny do wytwarzania mikroprądów
IL255498A (en) Treatment of pruritus
PT3393517T (pt) Ácido acetilsalicílico para utilização no tratamento de influenza moderada a grave
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
IL257803B (en) Peptide analogs derived from vdac1
ZA201801872B (en) Use of trientine to deliver copper to ischemic tissue
GB201504211D0 (en) Use of peptides
GB201419122D0 (en) Improvements relating to auction mechanisms
GB201418283D0 (en) Production of anti-microbial peptides